RT Journal Article
T1 Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia
A1 Beltrán-Camacho, Lucía
A1 Rojas-Torres, Marta
A1 Durán-Ruiz, Mᵃ Carmen
K1 Critical limb ischemia
K1 Neovascularization
K1 Angiogenesis
K1 Arteriogenesis
K1 Cell therapy
K1 Secretomes
K1 Angiogenesis
K1 Isquemia
K1 Neovascularization
K1 Tratamiento basado en trasplante de células y tejidos
K1 Extremidades
AB Critical limb ischemia (CLI) constitutes the most severe form of peripheral arterial disease (PAD), it is characterized by progressive blockade of arterial vessels, commonly correlated to atherosclerosis. Currently, revascularization strategies (bypass grafting, angioplasty) remain the first option for CLI patients, although less than 45% of them are eligible for surgical intervention mainly due to associated comorbidities. Moreover, patients usually require amputation in the short-term. Angiogenic cell therapy has arisen as a promising alternative for these "no-option" patients, with many studies demonstrating the potential of stem cells to enhance revascularization by promoting vessel formation and blood flow recovery in ischemic tissues. Herein, we provide an overview of studies focused on the use of angiogenic cell therapies in CLI in the last years, from approaches testing different cell types in animal/pre-clinical models of CLI, to the clinical trials currently under evaluation. Furthermore, recent alternatives related to stem cell therapies such as the use of secretomes, exosomes, or even microRNA, will be also described.
PB MDPI
YR 2021
FD 2021-02-26
LK http://hdl.handle.net/10668/3661
UL http://hdl.handle.net/10668/3661
LA en
NO Beltrán-Camacho L, Rojas-Torres M, Durán-Ruiz MC. Current Status of Angiogenic Cell Therapy and Related Strategies Applied in Critical Limb Ischemia. Int J Mol Sci. 2021 Feb 26;22(5):2335
DS RISalud
RD Apr 11, 2025